With the wide use of direct-acting antiviral agents (DAAs), more and more patients with chronic hepatitis C achieve sustained virological response; however, no consensus has been reached on the application of DAAs in the treatment of hepatitis C virus-related hepatocellular carcinoma (HCC). This article summarizes and evaluates related issues in this field, including whether antiviral therapy with DAAs in patients with hepatitis C can increase the incidence or recurrence rate of HCC, as well as whether DAAs can be used for hepatitis C in HCC patients after antitumor treatment and the efficacy of DAAs in such patients.
随着直接抗病毒药物（DAAs）的广泛使用，越来越多的慢性丙型肝炎患者可获得持久病毒学应答，然而DAAs在丙型肝炎病毒相关性肝细胞癌治疗应用尚有争议。该领域存在的相关问题：丙型肝炎患者经过DAAs抗病毒治疗是否增加肝细胞癌的发生率或复发率；肝细胞癌患者经过相应的抗肿瘤治疗后，合并的丙型肝炎是否可以应用DAAs治疗以及疗效如何等，包括引起公众关注的问题。.
Keywords: Carcinoma, hepatocellular; Direct antiviral drugs; Hepatitis C, chronic; Therapy.